| Literature DB >> 33257739 |
Adi Elias1, Reham Agbarieh2, Walid Saliba2,3, Johad Khoury4, Fadel Bahouth5,6, Jeries Nashashibi7, Zaher S Azzam8,2.
Abstract
Acute decompensated heart failure (ADHF) is one of the leading causes for hospitalization and mortality. Identifying high risk patients is essential to ensure proper management. Sequential Organ Function Assessment Score (SOFA) is considered an excellent score to predict short-term mortality in sepsis and other life-threatening conditions. To assess the capability of SOFA score in predicting short-term mortality in ADHF. We retrospectively identified patients with first hospitalization with primary diagnosis of ADHF between the years (2008-2018). The SOFA score was calculated for all patients. A total 3232 patients were included in the study. The SOFA score was significantly associated with in-hospital mortality and 30-day mortality. The odds ratios for 1-point increase in the SOFA score were 1.86 (95% CI 1.68-1.96) and 1.627 (95% CI 1.523-1.737) respectively. The SOFA Score demonstrated a good predictive accuracy. The areas under the curve of receiver operating characteristic curves for in-hospital mortality and 30-day mortality were 0.765 (95% CI 0.733-0.798) and 0.706 (95% CI 0.676-0.736) respectively. SOFA score is associated with increased risk of short-term mortality in ADHF. SOFA can be used as a complementary risk score to screen high risk patients who need strict monitoring.Entities:
Year: 2020 PMID: 33257739 PMCID: PMC7705654 DOI: 10.1038/s41598-020-77967-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flow chart of inclusion of acute decompensated heart failure cases in analyses.
Figure 2SOFA score frequency distribution in the study cohort.
Distribution of demographic, clinical characteristics according to SOFA score categories.
| All 3233 (100%) | Category 1 (0–1 points) 1356 (41.9%) | Category 2 (2–3 points) 1370 (42.4%) | Category 3 (4–5 points) 402 (12.4%) | Category 4 (> 5 points) 105 (3.2%) | P Value | |
|---|---|---|---|---|---|---|
| Age | 75.15 ± 11.89 | 74 ± 12 | 76.32 ± 11.5 | 74.7 ± 12.36 | 74 ± 11.52 | < 0.001 |
| Female Gender | 1544 (47.8%) | 766 (56.5%) | 602 (43.9%) | 140 (34.8%) | 36 (34.3%) | < 0.001 |
| IHD | 1794 (55.5%) | 686 (50.6%) | 808 (59.0%) | 237 (59.0%) | 63 (60.0%) | < 0.001 |
| DM | 1735 (53.7%) | 733 (54.1%) | 738 (53.9%) | 219 (54.5%) | 45 (42.9%) | .161 |
| Hypertension | 2696 (83.4%) | 1150 (84.8%) | 1148 (83.8%) | 324 (80.6%) | 74 (70.5%) | < 0.001 |
| CKD | 886 (27.4%) | 216 (15.9%) | 465 (33.9%) | 164 (40.8%) | 41 (39.0%) | < 0.001 |
| COPD | 492 (15.2%) | 201 (14.8%) | 209 (15.3%) | 68 (16.9%) | 14 (13.3%) | .717 |
| Normal EF (50–70%) | 1086 (33.6%) | 481 (35.5%) | 474 (34.6%) | 107 (26.6%) | 24 (22.9%) | 0.001 |
| Mild EF (40–50%) | 293 (9.1%) | 126 (9.3%) | 120 (8.8%) | 43 (10.7%) | 4 (3.8%) | 0.001 |
| Moderate EF (30–40%) | 345 (10.7%) | 162 (11.9%) | 135 (9.9%) | 37 (9.2%) | 11 (10.5%) | 0.001 |
| Severely Reduced EF (< 30%) | 500 (15.5%) | 202 (14.9%) | 203 (14.8%) | 73 (18.2%) | 22 (21.0%) | 0.001 |
| Missing Echocardiography | 1009 (31.2%) | 385 (28.4%) | 438 (32.0%) | 142 (35.3%) | 44 (41.9%) | 0.001 |
| GFR | 51.1 ± 7.4 | 65 ± 26 | 43 ± 22.5 | 35.8 ± 25.4 | 33.6 ± 3.6 | < 0.001 |
| Creatinine | 1.57 ± 1 | 1 ± 0.29 | 1.7 ± 0.71 | 2.61 ± 1.75 | 2.86 ± 2 | < 0.001 |
| BUN | 32 ± 18.64 | 22.59 ± 9.13 | 35.69 ± 17 | 47.81 ± 23.9 | 53 ± 30.5 | < 0.001 |
| Hemoglobin | 11.6 ± 2 | 11.9 ± 1.9 | 11.4 ± 2 | 11.24 ± 2 | 11.7 ± 2.3 | < 0.001 |
| Platelets | 299 ± 90 | 254 ± 85 | 380 ± 90 | 201 ± 103 | 205 ± 100 | < 0.001 |
| SOFA | 2 ± 1.5 | 0.69 ± 0.46 | 2.38 ± 0.48 | 4.35 ± 0.47 | 6.5 ± 0.78 | < 0.001 |
| Beta Blockers** | 2031 (62.8%) | 872 (64.3%) | 860 (62.8%) | 241 (60.0%) | 58 (55.2%) | 0.15 |
| ACE Inhibitors** | 1535 (47.5%) | 704 (51.9%) | 628 (45.8%) | 154 (38.3%) | 49 (46.7%) | < 0.001 |
| K sparing** | 507 (15.7%) | 190 (14.0%) | 217 (15.8%) | 76 (18.9%) | 24 (22.9%) | 0.017 |
| Diuretics** | 1980 (61.2%) | 703 (51.8%) | 923 (67.4%) | 281 (69.9%) | 73 (69.5%) | < 0.001 |
| Length of stay (days) | 8.08 ± 8.9 | 6.32 ± 6.45 | 8.46 ± 9.47 | 10.77 ± 10.41 | 15.54 ± 14.97 | < 0.001 |
**Drugs at admission.
Figure 3The risk of in-hospital and 30 day mortality according to SOFA score categories.
Figure 4Kaplan–Meier survival curves according to SOFA score categories.
The risk for in-hospital and 30 of death according to SOFA score categories.
| System | In Hospital mortality odds ratio (95% CI) | P value | 30 Day mortality odds ratio (95% CI) | P value |
|---|---|---|---|---|
| Category 1 (0–1 points) | Reference | – | Reference | – |
| Category 2 (2–3 points) | 2.875 (1.905–4.337) | < 0.001 | 1.975 (1.477–2.641) | < 0.001 |
| Category 3 (4–5 points) | 9.803 (6.379–15.065) | < 0.001 | 5.8 (4.2–8.02) | < 0.001 |
| Category 4 (> 5 points) | 29.844 (17.695–50.335) | < 0.001 | 15.527 (9.91–24.3) | < 0.001 |
| Crude | 1.86 (1.68–1.96) | < 0.001 | 1.627 (1.523–1.737) | < 0.001 |
| Model** | 1.874 (1.719–2.04) | < 0.001 | 1.657 (1.541–1.781) | < 0.001 |
*OR for each 1 point increase in SOFA.
**Multivariable model adjustment for Age, Gender, Hemoglobin, Hypertension, COPD, CKD, IHD, Beta Blocker, ACE-I, ARB, Diuretics, Ejection Fraction Category.
The association between each SOFA individual component with in-hospital and 30 day mortality.
| System | In hospital mortality odds ratio (95% CI) | P value | 30 Day mortality odds ratio (95% CI) | P value |
|---|---|---|---|---|
| Neurologic | 2.024 (1.777–2.305) | < 0.001 | 1.786 (1.57–2.02) | < 0.001 |
| Hemodynamic | 6.213 (4.852–7.957) | < 0.001 | 4.06 (3.325–4.95) | < 0.001 |
| Respiratory | 1.140 (0.993–1.308) | 0.063 | 0.943 (0.841–1.057) | 0.31 |
| Liver | 1.501 (1.194–1.886) | < 0.001 | 1.458 (1.197–1.776) | < 0.001 |
| Renal | 1.512 (1.336–1.711) | < 0.001 | 1.42 (1.278–1.579) | < 0.001 |
| Platelets | 1.513 (1.210–1.892) | < 0.001 | 1.4 (1.151–1.706) | < 0.001 |
Figure 5Area under the receiver operating characteristic curve (AUC) for predicting in-hospital mortality (A) and 30-day mortality (B) based on SOFA score.
Figure 6A. Observed vs predicted probability of in hospital mortality among predicted risk deciles. In (A) the dashed line is the identity line. The solid line represents the regression line. (B) Predicted probability vs observed probability of in hospital mortality.
Sensitivity, specificity, PPV, NPV at various threshold of the SOFA Score.
| Cutoff | Sensitivity | Specificity | PPV (%) | NPV (%) |
|---|---|---|---|---|
| > 0 | 97.93 | 13.61 | 8.4 | 98.8 |
| > 1 | 86.78 | 44.27 | 11.2 | 97.6 |
| > 2 | 69.83 | 71.21 | 16.4 | 96.7 |
| > 3 | 50.00 | 87.09 | 23.9 | 95.6 |
| > 4 | 32.64 | 94.42 | 32.1 | 94.5 |
| > 5 | 18.18 | 97.96 | 41.9 | 93.7 |
| > 6 | 7.85 | 99.40 | 51.4 | 93.0 |
| > 7 | 3.31 | 99.77 | 53.3 | 92.7 |
| > 8 | 0.83 | 100.00 | 100.0 | 92.6 |
PPV positive predictive value; NPV negative predictive value.
Comparison of the SOFA score to other risk scores (n = 2725).
| Risk scores | In Hospital Mortality | P* | 30 Day mortality | P* |
|---|---|---|---|---|
| AUC (95% CI) | AUC (95% CI) | |||
| SOFA | 0.773 (0.757–0.789) | – | 0.703 (0.686–0.720) | – |
| GWTG-HF | 0.752 (0.735–0.768) | 0.382 | 0.735 (0.718–0.751) | 0.126 |
| ADHERE | 0.591 (0.572–0.609) | < 0.001 | 0.584 (0.565–0.602) | < 0.001 |
| Framingham | 0.501 (0.482–0.519) | < 0.001 | 0.526 (0.507–0.545) | < 0.001 |
*P value for the difference in AUC of the SOFA score and the other scores (DeLong test).
Figure 7Decision curves for the SOFA score prediction of mortality . The net benefit (y-axis) of using the prediction model to guide clinical decision is plotted in relation to assuming that no one is at risk (all negative), that all are at risk (all positive). In-hospital mortaltiy and 30 day mortality are calculated based on the SOFA, GWTG-HF, Framingham and ADHERE score.